Namzaric gets FDA approval for expanded label

SILVER SPRING, Md. — Allergan and Adamas Pharmaceuticals on Tuesday announced an expanded label for their Namzaric (memantine and donepezil hydrochlorides). It can now be used by patients with moderate to severe Alzheimer’s disease. 

 

Patients currently stabilized on Aricept (donepezil HCL, 10 mg) can begin combination therapy with Namzaric. 

 

"Namzaric offers the benefits of combining two products that each work differently  to treat moderate to severe Alzheimer's disease while at the same time reducing the number of pills a patient and their caregivers need to administer each day," Allergan chief medical officer Dr. Gavin Corcoran, said. "At Allergan, we're proud to continue developing products and supporting new programs that can help patients and their caregivers as they navigate this complex disease."

 

The expanded label also comes with two new dosage strengths, which the companies said will be available in September.